Invivyd, Inc. (IVVD) Research

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.

Market snapshot

Symbol
IVVD
Price
$0.97
Day change
+4.16%
Market cap
$128.7M
P/E ratio
-3.87x
52-week range
0.483-3.07
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$9.50

Recent news

  • Invivyd doses first participants in Phase 3 COVID-19 trial

    Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the prevention of COVID-19 against and alongside an mRNA vaccine. The randomized, double-blind trial is evaluating the safety, tolerability and immune response of VYD2311 on its own, an mRNA COVID-19 vaccine on its own, and VYD2311 given together with a COVID-19 vaccine in healthy adults, the New Haven, Connecticut-based company said.

  • Invivyd doses first participants in Phase 3 COVID-19 trial

    Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the...

  • Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

    The company said its Phase 3 DECLARATION trial evaluating VYD2311 for COVID-19 prevention has reached a key interim milestone.

Peer companies

  • C4 Therapeutics, Inc. (CCCC)
  • Codexis, Inc. (CDXS)
  • Genfit S.A. (GNFT)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • Neonc Technologies Holdings, Inc. (NTHI)
  • OmniAb, Inc. (OABI)
  • Orchestra BioMed Holdings, Inc. (OBIO)
  • Sangamo Therapeutics, Inc. (SGMO)

Recent insider activity

  • Royan Ajay — A-Award (50000 shares) on 2026-05-19
  • MCLAUGHLIN KEVIN F — A-Award (50000 shares) on 2026-05-19
  • MCGUIRE TERRANCE — A-Award (50000 shares) on 2026-05-19
  • Elia Marc — A-Award (50000 shares) on 2026-05-19
  • BOLNO PAUL — A-Award (32876 shares) on 2026-05-19

Open Invivyd, Inc. (IVVD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.